Valeant Adds $1 Billion to Salix Offer, Amid Bid Battle
Valeant announced that it would increase its original acquisition agreement with Salix to approximately $15.8 billion.
In February 2015, Valeant announced that it would acquire Salix for $158 per share in cash, totaling approximately $14.5 billion (including company debt). On March 16, 2015, Valeant announced that it would increase its offer to $173 per share in cash coming to approximately $15.8 billion, over one billion more than the original offer.
According to The Wall Street Journal, this increase comes after a cash-and-stock bid of $172.56 from Endo International, a specialty pharmaceuticals company. Per the agreement, if all of the conditions to the tender have not been satisfied by Apr. 8, 2015, the offer price will revert back to $158 per share, according to the press release.
Source: Valeant
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
